Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Veronika DillJohanna KauschingerRichard T HauchLars BuschhornTimo O OdiniusCatharina Müller-ThomasRitu MishraMichele C KynclBurkhard SchmidtPeter M ProdingerDirk HempelFrauke BellosAlexander HölleinWolfgang KernTorsten HaferlachJulia Slotta-HuspeninaFlorian BassermannChristian PeschelKatharina S GötzeIrene C WaizeneggerUlrike HöckendorfPhilipp J JostStefanie Jilg

Published in: European journal of haematology (2019)

Volasertib offers a promising therapeutic approach in patients with adverse prognostic profile. RIPK3 and MCL-1 might be potential biomarkers for sensitivity to volasertib treatment.

Keyphrases

emergency department
adverse drug
electronic health record
drug induced
smoking cessation